Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway.
Coagulation and fibrinolysis are processes that form and dissolve fibrin, respectively. These processes are exquisitely regulated and protect the organism from excessive blood loss or excessive fibrin deposition. Regulation of these cascades is accomplished by a variety of mechanisms involving cellular responses, flow, and protein-protein interactions. With respect to regulation mediated by protein-protein interaction, the coagulation cascade appears to be more complex than the fibrinolytic cascade because it has more components. Yet each cascade is regulated by initiators, cofactors, feedback reactions, and inhibitors. Coagulation is also controlled by an anticoagulant pathway composed of (minimally) thrombin, thrombomodulin, and protein C.(1) Protein C is converted by the thrombin/thrombomodulin complex to activated protein C (APC), which catalyzes the proteolytic inactivation of the essential cofactors required for thrombin formation, factors Va and VIIIa. An analogous antifibrinolytic pathway has been identified recently. This pathway provides an apparent symmetry between coagulation and fibrinolysis and is also composed of thrombin, thrombomodulin, and a zymogen that is activated to an enzyme. The enzyme proteolytically inactivates a cofactor to attenuate fibrinolysis. However, unlike APC, which is a serine protease, the antifibrinolytic enzyme is a metalloprotease that exhibits carboxypeptidase B-like activity. Within a few years of each other, 5 groups independently described a molecule that accounts for this antifibrinolytic activity. We refer to this molecule as thrombin activatable fibrinolysis inhibitor (TAFI), a name that is based on functional properties by which it was identified, assayed, and purified. (Because of the preferences of some journals "activatable" is occasionally referred to as "activable.") This review will encompass a historical account of efforts to isolate TAFI and characterize it with respect to its activation, activity, regulation, and potential function in vivo.
Bajzar
L
L
Hamilton Civic Hospitals Research Centre and McMaster University, Hamilton, Ontario, Canada. lbajzar@thrombosis.hhscr.org
D000933:Antifibrinolytic Agents / Q000302:isolation & purification* / Q000378:metabolism / Q000494:pharmacology; D001665:Binding Sites; D025901:Carboxypeptidase B2; D002268:Carboxypeptidases / Q000235:genetics / Q000302:isolation & purification* / Q000378:metabolism / Q000494:pharmacology; D002474:Cell-Free System; D002846:Chromatography, Affinity; D004591:Electrophoresis, Polyacrylamide Gel; D004789:Enzyme Activation / Q000187:drug effects; D004795:Enzyme Stability; D005342:Fibrinolysis; D006801:Humans; D007527:Isoenzymes / Q000302:isolation & purification; D007700:Kinetics; D011486:Protein C / Q000378:metabolism; D013379:Substrate Specificity; D009626:Terminology as Topic; D013917:Thrombin / Q000502:physiology*; D018180:Thrombomodulin / Q000378:metabolism
D000933:Antifibrinolytic Agents; D007527:Isoenzymes; D011486:Protein C; D018180:Thrombomodulin; D002268:Carboxypeptidases; D025901:Carboxypeptidase B2; D013917:Thrombin